1439368-01-0

Basic information

• Product Name: (2R,3S)-2-[{[(4-cyclohexylphenyl)methoxy]carbonyl}amino]-3-hydroxybutanoic acid
• Synonyms: (2R,3S)-2-[{[(4-cyclohexylphenyl)methoxy]carbonyl}amino]-3-hydroxybutanoic acid
• CAS NO: 1439368-01-0
• Molecular Weight: 335.4
• Mol File: 1439368-01-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2R,3S)-2-[{[(4-cyclohexylphenyl)methoxy]carbonyl}amino]-3-hydroxybutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S)-2-[{[(4-cyclohexylphenyl)methoxy]carbonyl}amino]-3-hydroxybutanoic acid(1439368-01-0)
• EPA Substance Registry System: (2R,3S)-2-[{[(4-cyclohexylphenyl)methoxy]carbonyl}amino]-3-hydroxybutanoic acid(1439368-01-0)

Safety Data

• Hazardous Substances Data: 1439368-01-0(Hazardous Substances Data)

Upstream product

• 20029-52-1 4-cyclohexylbenzoic acid 
• 1659-31-0 2,2'-dipyridyl carbonate 
• 632-20-2 D-Threonine 
• 208259-47-6 4-cyclohexylphenylmethyl alcohol 

Downstream Products

• 1439366-93-4 (4-cyclohexylphenyl)-methyl N-[(2S,3R)-2-methyl-4-oxo-oxetan-3-yl]-carbamate 

Relevant articles and documents

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.